ORICライブシグナル | Getagraph.comで利益を最大化

買う 107862 min ago

@ $11.31

発行日: 15 2月 2024 @ 04:07

リターン: -24.88%

前回のシグナル: 2月 14 - 03:45

前回のシグナル: 売る

リターン: -1.65 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:48):

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States...

Stats
本日の出来高	138 113
平均出来高	570 877
時価総額	572.75M
EPS	$0 ( 2024-03-21 )
次の収益日	( $-0.440 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.33
ATR14	$0.0180 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Chacko Jacob	Sell	40 000	Common Stock
2024-02-06	Chacko Jacob	Sell	13 958	Common Stock
2024-02-07	Chacko Jacob	Sell	26 042	Common Stock
2024-01-02	Multani Pratik S	Buy	180 000	Stock Option (right to buy)
2024-01-02	Multani Pratik S	Buy	30 000	Restricted Stock Unit

INSIDER POWER
54.58
Last 99 transactions
Buy: 6 373 472 \| Sell: 3 807 004

ボリューム相関

長: 0.29 (neutral)

短: -0.44 (neutral)

Signal:(47.57) Neutral

Oric Pharmaceuticals Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Oric Pharmaceuticals Inc 相関 - 通貨/商品

0.88
( strong )

0.94
( very strong )

0.00
( neutral )

0.80
( strong )

0.79
( moderate )

-0.79
( moderate negative )

Oric Pharmaceuticals Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2023
収益:	$0
総利益:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2022
収益:	$0
総利益:	$-966 000 (0.00 %)
EPS:	$-2.31

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-2.07

Financial Reports:

No articles found.

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.